STRO

Sutro Biopharma Inc. (STRO) | Rumor.io

Sutro Biopharma

STRO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,328

Bullish sentiment (50-day avg)57%

Price to earnings ratio-0.71

Market capitalization265.8M

Earnings per share-17.4

Dividend yield (TTM)—

Revenue (annual)102.5M

Net income (annual)-191.1M

Social

What share of all stock conversation is about STRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Feb 10

Sutro Biopharma, Inc. (STRO) raised $110M in a secondary offering, which is equal to its market capitalization.
The company plans to use the funds to support its clinical trials, including the STRO-004 study, with a data readout expected in mid-2026.
Investors are optimistic about STRO's long-term potential, despite the dilution from the offering, with some analysts viewing it as a bullish sign for the company's prospects.

Generated by AI

Sentiment

Of the messages about STRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	33.33% -41.67	85.71% +11.68
Bearish	0%	0%	66.67% +41.67	14.29% -11.68

Mar 17

$STRO is expected to benefit from a licensing deal with a major pharmaceutical company, with the author speculating that the deal is imminent.
The company's recent reprioritization news was seen as oversold, and the author believes the stock is due for a reversal.
A major milestone payment of $7 million from Ipsen is expected to trigger, which could lead to a significant increase in the stock price.

Generated by AI

Topics

Of the messages about STRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	83.24%
Analysts	—	—	0%	8.65%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	8.11%

Apr 2

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors, with up to $900m in upfront and milestone payments.
Sutro Biopharma prices $75m underwritten offering, raising funds for advancement of cancer therapies.
Ipsen secures exclusive global rights to Sutro Biopharma's STRO-003 ADC, with Sutro eligible to receive up to $900m in potential payments.

Generated by AI

Community

Of the messages about STRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	46.9%
Newcomers	0%	0%	0%	53.1%

Regulars· May 3

$IMGN's Mirasol data has compromised $STRO's accelerated filing plan, casting doubt on its path to approval.
The possibility of accelerated approval for STRO-002 is now almost impossible due to the recent data from $IMGN.
$STRO's quarterly revenue growth rate of 300.10% YoY has ranked 160 out of 5755 companies in the database.

Newcomers· Feb 10

$STRO has seen a significant increase in stock price despite dilution, with investors focusing on the company's longer-term biotech optionality.
Investors are concerned about the company's ability to develop a platform, with some comparing them to "funding zombies."
$STRO has raised $110M through a public offering, which will fund the development of STRO-004 and a collaboration with Astellas, with a mid-2026 data readout as a key milestone.

Generated by AI

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026. Mr. Donigian brings more than 20 years of biotechnology industry experience, with a background in business development, corporate strategy

23h agoYahoo Finance

Mackay Gold & Silver Ramps Up Comstock Drilling With Second Rig on Historic Sutro Target

Tipranks Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about STRO also mention

#	Name	Attention
1	Vaxcyte Inc.PCVX	0%0
2	Kura Oncology, Inc.KURA	0%+0
3	Genmab A/S American Depositary SharesGMAB	0%0
4	BioAtla Inc.BCAB	0%new
5	Bicycle Therapeutics plc - ADRBCYC	0%0
6	TScan Therapeutics, Inc.TCRX	0%0
7	ADC Therapeutics S.A.ADCT	0%0
8	CytomX Therapeutics, Inc.CTMX	0%0
9	Nkarta, Inc.NKTX	0%0
10	AVRO - AVROBIO, Inc.	——

Sutro Biopharma Inc.

Healthcare
Biotechnology

Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms. These technologies support the discovery, development, and manufacture of biologic drug candidates intended for oncology and other immune-related diseases. Sutro Biopharma’s work centers on creating precisely engineered therapies for solid tumors and hematologic cancers, while also supporting collaborative research and development efforts with pharmaceutical partners. Headquartered in South San Francisco, California, Sutro Biopharma plays a specialized role in the biopharmaceutical market by combining protein engineering, drug conjugation, and therapeutic development within a single platform-driven approach.

Website

Location

111 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about STRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Feb 10

Sutro Biopharma, Inc. (STRO) raised $110M in a secondary offering, which is equal to its market capitalization.
The company plans to use the funds to support its clinical trials, including the STRO-004 study, with a data readout expected in mid-2026.
Investors are optimistic about STRO's long-term potential, despite the dilution from the offering, with some analysts viewing it as a bullish sign for the company's prospects.

Generated by AI

Sentiment

Of the messages about STRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	33.33% -41.67	85.71% +11.68
Bearish	0%	0%	66.67% +41.67	14.29% -11.68

Mar 17

$STRO is expected to benefit from a licensing deal with a major pharmaceutical company, with the author speculating that the deal is imminent.
The company's recent reprioritization news was seen as oversold, and the author believes the stock is due for a reversal.
A major milestone payment of $7 million from Ipsen is expected to trigger, which could lead to a significant increase in the stock price.

Generated by AI

Topics

Of the messages about STRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	83.24%
Analysts	—	—	0%	8.65%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	8.11%

Apr 2

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors, with up to $900m in upfront and milestone payments.
Sutro Biopharma prices $75m underwritten offering, raising funds for advancement of cancer therapies.
Ipsen secures exclusive global rights to Sutro Biopharma's STRO-003 ADC, with Sutro eligible to receive up to $900m in potential payments.

Generated by AI

Community

Of the messages about STRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	46.9%
Newcomers	0%	0%	0%	53.1%

Regulars· May 3

$IMGN's Mirasol data has compromised $STRO's accelerated filing plan, casting doubt on its path to approval.
The possibility of accelerated approval for STRO-002 is now almost impossible due to the recent data from $IMGN.
$STRO's quarterly revenue growth rate of 300.10% YoY has ranked 160 out of 5755 companies in the database.

Newcomers· Feb 10

$STRO has seen a significant increase in stock price despite dilution, with investors focusing on the company's longer-term biotech optionality.
Investors are concerned about the company's ability to develop a platform, with some comparing them to "funding zombies."
$STRO has raised $110M through a public offering, which will fund the development of STRO-004 and a collaboration with Astellas, with a mid-2026 data readout as a key milestone.

Generated by AI

Sutro Biopharma

Social

Feb 10

Sentiment

Mar 17

Topics

Apr 2

Community

Regulars· May 3

Newcomers· Feb 10

News

Sutro Biopharma appoints Lucas Donigian as business head

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Mackay Gold & Silver Ramps Up Comstock Drilling With Second Rig on Historic Sutro Target

Citizens cuts Sutro Biopharma stock price target on revenue miss

Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates

Sutro reports early clinical responses from STRO-004 cancer trial

Also Discussed

Sutro Biopharma Inc.

Company Information

Location

News

Sutro Biopharma appoints Lucas Donigian as business head

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Mackay Gold & Silver Ramps Up Comstock Drilling With Second Rig on Historic Sutro Target

Citizens cuts Sutro Biopharma stock price target on revenue miss

Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates

Sutro reports early clinical responses from STRO-004 cancer trial

Also Discussed

Social

Feb 10

Sentiment

Mar 17

Topics

Apr 2

Community

Regulars· May 3

Newcomers· Feb 10